Unravel is a clinical-stage biotech company whose Agile Medicine approach brings patients into drug discovery from the start, using individual patient RNA to power AI-enabled therapeutic mechanism discovery. The approach offers patients potential treatments today with off-label use of existing medications while unlocking clinical signals with unprecedented speed. Unravel has delivered direct-to-patient personalized medicine serving over 1,500 individuals with 120 different disorders. Unravel is also conducting two clinical trials of RVL-001 for treatment of Rett and Pitt Hopkins syndromes and is developing four additional therapies to treat other complex disorders, while pursuing ALS treatments in a global collaboration as a recipient of the ALS Longitude Prize.
MassBio Member Spotlight: Unravel Biosciences, Inc.
Location: 196 Boston Ave, Suite 1000, Medford, MA
Therapeutic area(s): Complex and rare disorders, personalized medicine
Leadership:
- Richard Novak, CEO
- Frederic Vigneault, Chief Scientific Officer
- Neal Muni, Chief Medical Officer
Website: unravel.bio
